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Fibrosis is caused by scar tissue formation in internal organs and is
associated with 45% of deaths in the United States. Two closely
related human serum proteins, serum amyloid P (SAP) and C-reactive
protein (CRP), strongly affect fibrosis. In multiple animal models, and
in Phase 1 and Phase 2 clinical trials, SAP affects several aspects of the
innate immune system to reduce fibrosis, whereas CRP appears to
potentiate fibrosis. However, SAP and CRP bind the same Fcγ receptors
(FcγR) with similar affinities, and why SAP and CRP have opposing
effects is unknown. Here, we report that SAP but not CRP binds the
receptor DC-SIGN (SIGN-R1) to affect the innate immune system, and
that FcγR are not necessary for SAP function. A polycyclic aminothia-
zole DC-SIGN ligand and anti–DC-SIGN antibodies mimic SAP effects in
vitro. In mice, the aminothiazole reduces neutrophil accumulation in a
model of acute lung inflammation and, at 0.001 mg/kg, alleviates
pulmonary fibrosis by increasing levels of the immunosuppressant
IL-10. DC-SIGN (SIGN-R1) is present on mouse lung epithelial cells,
and SAP and the aminothiazole potentiate IL-10 production from these
cells. Our data suggest that SAP activates DC-SIGN to regulate the
innate immune system differently from CRP, and that DC-SIGN is a
target for antifibrotics.
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Fibrosing diseases such scleroderma, pulmonary fibrosis, andrenal fibrosis are caused by aberrant scar tissue formation in
internal organs and are associated with 45% of deaths in the
United States (1). At a fibrotic lesion, monocytes leave the
blood, enter the tissue, and differentiate into cells such as mac-
rophages and fibrocytes (2). Fibrocytes and macrophages then
secrete extracellular matrix (ECM) proteins, ECM modifying
enzymes, and/or cytokines such as IL-4 to promote scar tissue
formation and fibrosis (3, 4).
Pentraxins are a family of highly conserved secreted proteins that
have a profound effect on the development of fibrosis and the
regulation of the innate immune system (5–7). The pentraxin serum
amyloid P (SAP) reduces neutrophil activation and recruitment (8,
9), inhibits the differentiation of monocytes into fibroblast-like cells
called fibrocytes (8, 10), and promotes IL-10–secreting macro-
phages (11–13). In animal models and two human trials (6, 14, 15),
injections of SAP decrease fibrosis, indicating that SAP has a
dominant effect on a disease that is mediated in part by the innate
immune system. Conversely, the closely related pentraxin C-reactive
protein (CRP) is proinflammatory and promotes fibrosis (5, 16).
However, under some conditions, CRP decreases inflammation,
indicating that much remains to be understood about this molecule
(5, 17). Despite the strong effects of pentraxins on the innate im-
mune system and fibrosis (5, 6), little is known about their mech-
anism of action. For instance, pentraxins such as SAP and CRP
appear to bind the same Fcγ receptors (FcγR) with similar affinities
(7, 8, 18), but they generally have opposite effects. What causes this
functional difference is not known.
Dendritic cell-specific intercellular adhesion molecule-3-
grabbing nonintegrin (DC-SIGN/CD209) is a C-type lectin found
on dendritic cells, macrophages, and monocytes (19, 20). DC-
SIGN mainly binds to mannosylated and fucosylated proteins
(19, 20). Humans have DC-SIGN and L-SIGN, whereas mice
have eight DC-SIGN orthologs called SIGN-R1–8 (21). SIGN-
R1 most closely resembles DC-SIGN (21). DC-SIGN and SIGN-
R1 also bind sialylated IgG (sIgG) (20). This interaction appears
to be a protein:potein interaction and not a sialic acid:DC-SIGN
interaction (22). Both sIgGs and SAP have α(2,6)-linked termi-
nal sialic acids on the protein surface, and both sIgGs and SAP
alleviate inflammation in mice (6, 20, 23).
In this report, we show that in absence of all of the FcγR, neu-
trophils, monocytes, and macrophages still respond to SAP, in-
dicating that SAP uses other receptors. For SAP, we show that one
of the other receptors is DC-SIGN. We also found that anti–DC-
SIGN antibodies and a small-molecule DC-SIGN ligand mimic the
effects of SAP. The synthetic DC-SIGN ligand shows efficacy in
murine models of acute lung inflammation and pulmonary fibrosis.
In contrast to SAP, we find that CRP requires the FcγR to regulate
neutrophils and IL-10 secretion from macrophages, but not to
increase ICAM-I+ macrophages. This finding suggests that there
are additional CRP receptors that regulate macrophage polariza-
tion. Our findings suggest the presence of a previously unidentified
pentraxin target that accounts for the functional difference between
SAP and CRP, and which might be useful as a therapeutic target to
regulate the innate immune system and fibrosis.
Results
Fcγ Receptors Are Not Necessary for SAP Effects on the Innate
Immune System. SAP and CRP both bind FcγR, but have differ-
ent effects on the innate immune system (8, 18). To determine
the role of FcγR in SAP and CRP function, we examined the
effect of these proteins on mouse cells lacking all FcγR (FcγR
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quad KO). As previously observed, SAP and CRP decreased the
adhesion of C57BL/6 neutrophils to fibronectin (Fig. 1A) (8, 9).
However, when added to FcγR quad KO neutrophils, SAP but
not CRP significantly reduced neutrophil adhesion to fibronectin
(Fig. 1A).
In addition to reducing neutrophil adhesion, SAP inhibits the
differentiation of monocytes into fibroblast-like cells called
fibrocytes (8, 10) (Fig. 1B). In the absence of FcγR, SAP re-
duced but could not completely inhibit fibrocyte differentia-
tion (Fig. 1B). CRP had no effect on fibrocyte differentiation
(Fig. 1C) (10). The absence of FcγR did not alter this response
(Fig. 1C).
SAP potentiates CD206+ antiinflammatory macrophages (13)
(Fig. 1D). CRP, however, primarily promotes ICAM-I+ M1-like
inflammatory macrophages (16) (Fig. 1E). In our assays, both
SAP and CRP were able to polarize FcγR quad KO macro-
phages as determined by CD206 and ICAM-I expression (Fig. 1
D and E). In agreement with its antiinflammatory function, SAP
also increased IL-10 secretion from C57BL/6 and FcγR quad KO
macrophages (Fig. 1F). We also observed that CRP increased
IL-10 secretion from C57BL/6 macrophages but not from the
FcγR quad KO cells, indicating that some but not all effects of
CRP on macrophages are mediated by the FcγR (Fig. 1F). The
increase in IL-10 secretion in response to CRP has been ob-
served before (24, 25) and is most likely counteracted by CRP-
induced TNF-α and IL-12 under inflammatory conditions (16).
The related pentraxin PTX3 was also able to decrease neutrophil
adhesion and alter macrophage phenotype in absence of the
FcγR, although the PTX3-induced IL-10 secretion by macro-
phages was absent (Fig. S1). Together these results suggest that
contrary to the current model of SAP signaling, the FcγR are not
necessary for SAP effects. This observation suggests the presence
of additional SAP receptors. Conversely, CRP requires the FcγR
to reduce neutrophil adhesion and promote IL-10 secretion by
macrophages, but not to increase ICAM-I+ macrophages. This
finding indicates that some aspects of the CRP effect on mac-
rophages is mediated by an unknown receptor.
A B C D E F
Fig. 1. Fcγ receptors are necessary for some but not all effects of SAP and CRP. (A) Mouse neutrophils were incubated with 10 μg/mL of the indicated
pentraxin and TNF-α, and neutrophil adhesion to fibronectin was assayed, n = 3. (B and C) Mouse spleen cells were incubated with the indicated concen-
trations of pentraxin. After 5 d, the cells were fixed, stained, and fibrocytes were counted, n = 3–6. (D and E) Mouse bone marrow-derived macrophages were
polarized in 0 (control) or 10 μg/mL of the indicated pentraxin. Cells were then fixed and stained, n = 3. (F) Macrophages were polarized as in D, and IL-10
levels in the supernatants were measured, n = 3–8. n.s. (not significant relative to the control), *P < 0.05 (t test), (D) ×, P < 0.05 (t test relative to SAP in C57BL/6).
All values are mean ± SEM. Data were fit to sigmoidal dose–response curves with a variable Hill coefficient (B) or a line (C).
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Fig. 2. Glycosylation mediates some effects of SAP. (A) Desialylated SAP [SAP (NA)], SAP, glycosylated CRP (CRP A32N), CRP, and desialylated CRP A32N [CRP
A32N (NA)] were electrophoresed on SDS/PAGE gels and stained with silver stain. (B) Western blots of the samples in A were stained with Sambucus Nigra
lectin to detect α(2,6)-linked terminal sialic acids. (C) Human neutrophils were incubated with 0 (control) or 10 μg/mL of the indicated pentraxin to assess
neutrophil adhesion as in Fig. 1A, n = 3–5. (D and E) Human PBMC were incubated with the indicated concentrations of pentraxins. After 5 d, fibrocytes were
counted, n = 3–5. (F) Mouse spleen cells were incubated in the presence or absence of 10 μg/mL of the indicated pentraxin. Fibrocyte counts were normalized
to the no-pentraxin control, n = 3. (G) Mouse C57BL/6 bone marrow-derived macrophages were polarized in 0 (control) or 10 μg/mL of the indicated pen-
traxins. Cells were then stained for the indicated markers, n = 3. (H) Human macrophages were polarized by 3 μg/mL of the indicated protein and then
stained, n = 3. *P < 0.05, **P < 0.01 (t test). (F) +, P < 0.05 (t test relative to the no-protein control). (C–H) Values are mean ± SEM. (D and E) Data were fit to
sigmoidal dose–response curves with a variable Hill coefficient or a line where appropriate.
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SAP Glycosylation Mediates SAP Effects on the Innate Immune System.
CRP has sequence and structural similarity to SAP, and like SAP,
binds FcγR (5, 6). However, SAP and CRP have different effects
on monocyte and macrophage differentiation; for instance,
whereas SAP inhibits fibrocyte differentiation (8) and promotes
IL-10 secreting macrophages (3, 13), CRP has no effect on
fibrocyte differentiation (10) and promotes proinflammatory
macrophages (16). One possible reason for this functional differ-
ence is sequence divergence between SAP and CRP. However, we
previously found that mutating SAP surface amino acid residues
that are different between SAP and CRP has only a modest effect
on SAP function (8). An alternative cause of this functional dif-
ference may be a difference in SAP and CRP glycosylation: SAP is
glycosylated at N32 with α(2,6)-linked terminal sialic acids (23),
which is exposed on a soluble surface, whereas CRP has no gly-
cosylation (23). To determine whether the SAP glycosylation af-
fects its function, we enzymatically removed the terminal sialic
acids with neuraminidase. The desialylated SAP [SAP (NA)] could
no longer be detected on Western blots stained with Sambucus
Nigra lectin, which binds preferentially to α(2→6)-linked terminal
sialic acids (Fig. 2 A and B).
SAP and CRP as observed previously reduced human neu-
trophil adhesion to fibronectin (9) (Fig. 2C). However as com-
pared with SAP, SAP (NA) had a reduced effect on human
neutrophil adhesion and was unable to inhibit fibrocyte differ-
entiation when added to human PBMCs and mouse spleen cells
(Fig. 2 C–F). These findings indicate a significant functional role
for SAP glycosylation and provide a possible mechanism for the
immune cells to differentiate SAP from CRP. Furthermore,
these results suggest that a glycosylated CRP would be able to
“trick” the innate immune cells and mimic SAP effects. To ex-
amine this possibility, we mutated CRP at position 32 from an
alanine to an asparagine. The mutated CRP (CRP A32N) was
glycosylated and had a lower mobility on SDS/PAGE gels com-
pared with CRP (Fig. 2 A and B). However, on average only 40%
of CRP A32N monomers were sialylated (Fig. 2B). This lack of
complete sialylation is likely due to problems with recombinant
protein expression and/or sequence differences between SAP
and CRP (26). When tested on innate immune cells, CRP A32N
similar to CRP and SAP reduced human neutrophil adhesion
(Fig. 2C). However, unlike CRP, CRP A32N was able to inhibit
fibrocyte differentiation when added to human PBMC or mouse
spleen cells (Fig. 2 E and F). Furthermore, CRP A32N similar to
SAP did not require the FcγR to inhibit fibrocyte differentiation
(Fig. 2F).
In addition to regulating neutrophil adhesion and fibrocyte
differentiation, SAP and CRP can polarize macrophages (3, 11,
13). To examine the role of SAP glycosylation on macrophage
polarization, we added pentraxins to mouse and human macro-
phages. SAP and CRP A32N promoted CD206+ M2 macro-
phages from mouse bone marrow-derived macrophages (Fig.
2G), whereas CRP and SAP (NA) increased ICAM-I+ M1
macrophages (27) (Fig. 2G). We observed a similar trend in
human monocyte-derived macrophages, where SAP and CRP
A32N promoted CD163+ M2 macrophages (28), whereas SAP
(NA) and CRP potentiated ICAM-I+ M1 macrophages (Fig.
2H). Neuraminidase-treated CRP A32N was essentially in-
distinguishable from CRP in our assays (Fig. 2), indicating a role
of glycosylation in the effects of CRP A32N. Together, these
results indicate that SAP glycosylation allows the innate immune
cells to differentiate SAP from CRP and response appropriately
to different pentraxins.
SAP but Not CRP Binds to DC-SIGN To Regulate Immune Cells. Sia-
lylated IgG (sIgG) binds DC-SIGN to alter IgG responses (20).
Because SAP shares the same type of glycosylation as sIgG (23),
and SAP and the Fc domain of IgG bind to FcγR, we examined
the possibility that SAP might bind to DC-SIGN. We expressed
DC-SIGN on HEK293 cells and measured SAP binding to the
transfected cells (Fig. 3A and Fig. S2). We used mock-trans-
fected HEK293 cells to estimate the nonspecific binding. SAP
bound to DC-SIGN with a KD of 2.3 ± 1 μg/mL (19 ± 8 nM) and
a Hill coefficient of 0.7 ± 0.3 (Fig. 3A). CRP A32N also bound to
DC-SIGN (KD of 3.4 ± 0.3 μg/mL, Hill coefficient = 1.9 ± 0.4)
but with a lower affinity relative to SAP (Fig. 3A), suggesting that
the SAP:DC-SIGN interaction may involve protein:protein in-
teraction and, hence, not be limited to carbohydrate:lectin in-
teraction. As expected, SAP (NA), CRP, and neuraminidase
treated CRP A32N did not show detectable binding to DC-SIGN
(Fig. 3A). This observation suggests that SAP and CRP A32N
may bind to DC-SIGN to alter immune responses. To test this
possibility, we examined the effect of SAP on spleen cells from
mice lacking the mouse ortholog of human DC-SIGN, SIGN-R1.
The absence of SIGN-R1 significantly decreased the inhibitory
effect of SAP on fibrocyte differentiation (Fig. 3B). CRP A32N
and PTX3 were also unable to alter fibrocyte differentiation
from SIGN-R1–deficient spleen cells, suggesting that SIGN-R1
might mediate CRP A32N and PTX3 effects on fibrocyte dif-
ferentiation (Fig. 3C and Fig. S3).
A B C
D E F
G H I
Fig. 3. DC-SIGN activation affects neutrophils and monocyte-derived cells.
(A) DC-SIGN+ HEK293 cells were incubated with fluorescently labeled SAP,
CRP, CRP A32N, SAP (NA), or CRP A32N (NA), and binding was measured by
flow cytometry. Mock transfected cells were used to estimate the nonspecific
binding, n = 3. (B) The effect of SAP on fibrocyte differentiation in C57BL/6 and
SIGN-R1–deficient cells was assessed, n = 3–5. (C) Mouse spleen cells were in-
cubated with 0 or 10 μg/mL of the indicated pentraxin. Fibrocytes were counted
as a percent of the no-pentraxin control, n = 3–5. (D) Human neutrophils were
incubated with anti-DC-SIGN antibodies and then neutrophil adhesion to fibro-
nectin was assessed, n = 3. (E) Human PBMCs were incubated with the indicated
concentrations of a rabbit anti–DC-SIGN antibody or a rabbit isotype control.
After 5 d, fibrocytes were counted, n = 3–5. (F) Human macrophages were po-
larized with 1 μg/mL of the indicated antibody. Macrophages were then fixed
and stained, n = 3. (G) The effect of compound 1 on human neutrophil adhesion
to fibronectin was assessed, n = 3. (H) The effect of compound 1 on human
fibrocyte differentiation, n = 3. (I) Macrophage polarization by 10 pg/mL of
compound 1 was examined in human macrophages, n = 3. *P < 0.05 (t test).
All values are mean ± SEM. (A) Curves are fits to models of one-site binding
with variable Hill coefficient where appropriate. (B, D, G, and H) Data were
fit to sigmoidal dose–response curves with a variable Hill coefficient.
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DC-SIGN is expressed on macrophages, dendritic cells, and
monocytes (19, 20) (Fig. S4). Previously, DC-SIGN mRNA has
been observed in human neutrophils (29, 30). We were also able to
detect cell-surface DC-SIGN on human and mouse neutrophils
(Figs. S4A and S5). Because the majority of cells expressing DC-
SIGN appear to respond to SAP, we examined whether DC-SIGN
activation by antibodies can mimic SAP effects on neutrophils,
monocytes, and macrophages. Some, but not all, anti-human DC-
SIGN antibodies decreased human neutrophil adhesion to fibro-
nectin (Fig. 3D) and inhibited human fibrocyte differentiation
(IC50 = 2.4 ± 0.4 μg/mL) (Fig. 3E and Fig. S6 A and B). A different
subset of anti-DC-SIGN antibodies also altered macrophage phe-
notype and increased CD163+ macrophages similar to SAP and
CRP A32N (Fig. 3F and Fig. S6C). We observed similar effects
using F(ab2) fragments of anti-DC-SIGN antibodies, suggesting
that our results are Fc-independent and most likely involve DC-
SIGN activation by the antibodies (Fig. S6 D–F).
To further ascertain the role of DC-SIGN in SAP signaling, we
examined whether DC-SIGN activation using synthetic ligands
could mimic SAP effects. When added to immune cells, a polycyclic
aminothiazole DC-SIGN ligand (compound 1; shown as compound
4 in figure 2 of ref. 31) decreased human neutrophil adhesion (IC50
of 1.7 ± 0.3 μg/mL and a Hill coefficient of 2.6 ± 0.2) (Fig. 3G) and
inhibited human fibrocyte differentiation (IC50 = 1.2 ± 0.4 pg/mL,
Hill coefficient = 0.30 ± 0.01) (Fig. 3H) without affecting cell via-
bility below 0.1 μg/mL (Fig. S7 A and B). Other DC-SIGN ligands
also inhibited human fibrocyte differentiation, although with lower
potency (Fig. S8). In addition, compound 1 promoted CD163+ M2
macrophages (Fig. 3I). Compound 1 similarly reduced neutrophil
adhesion, inhibited fibrocyte differentiation, and promoted
M2 macrophages in FcγR quad KO cells (Fig. S9). However, in
SIGN-R1–deficient cells, compound 1 did not affect fibrocyte
differentiation (Fig. S7C). These data indicate that DC-SIGN
activation by antibodies or a synthetic ligand is sufficient to
mimic SAP effects in vitro. In addition, these results suggest that
SAP:DC-SIGN interaction may contribute to the functional
differences in SAP and CRP effects on the innate immune sys-
tem. However, it is not clear whether SAP glycosylation directly
binds DC-SIGN (carbohydrate:lectin interaction) or alters the
structure of SAP so that SAP can bind DC-SIGN similar to how
sIgG binds this receptor (protein:protein interaction) (32).
Compound 1 Reduces Neutrophil Accumulation in the Lungs of
Bleomycin-Treated Mice. SAP and PTX3 regulate neutrophil re-
cruitment in mice (9, 33). To determine whether SIGN-R1 ac-
tivation similarly affects neutrophils in mice, WT mice were
given bleomycin to induce acute lung inflammation. We then
injected the mice with compound 1 and examined neutrophil
accumulation in the lungs. We did not use anti–SIGN-R1 anti-
bodies because they would activate both SIGN-R1 and FcγR,
therefore confounding the results. As observed before (9), oro-
pharyngeal instillation of bleomycin significantly increased the
number of Ly6G+ neutrophils in the lungs (Fig. 4). When mice
were injected with compound 1 at 0.1 mg/kg on days 1 and 2 after
bleomycin, there was a significant decrease in Ly6G+ cells in the
lungs at day 3 compared with the bleomycin control (Fig. 4).
Bleomycin treatment also resulted in a significant increase in
CD11b+ macrophages and CD45+ immune cells in the bron-
choalveolar lavage (BAL) fluid (Fig. 4B). This increase in in-
filtrating cells was absent when mice were given compound 1
(Fig. 4B). Additionally in the post-BAL lungs, compound 1 re-
versed a bleomycin-induced decrease in CD11c+ cells (Fig. 4C).
However, compound 1 did not alter the number of CD11b+
macrophages in the lungs compared with the bleomycin control
(Fig. 4C). Our results indicate that DC-SIGN ligands such as
compound 1 can, similar to SAP and PTX3 (9, 33), reduce
neutrophil accumulation in mouse lungs following an insult.
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Fig. 4. Compound 1 decreases neutrophil accumulation in mouse lungs.
(A) Mice received oropharyngeal bleomycin on day 0 to induce acute re-
spiratory distress syndrome. The control mice received saline. Mice were then
treated with i.p. injections of 0.1 mg/kg of compound 1 (C1) or an equal vol-
ume of vehicle control on days 1 and 2. On day 3, the mice were euthanized
and lungs after BAL were stained for the neutrophil marker Ly6G. Images are
representative of three independent experiments. (Scale bar: 100 μm.) (B) BAL
cells were stained for the indicatedmarkers, n = 4. (C) After collecting the BAL,
lungs were stained for the indicated markers, n = 4. *P < 0.05 (one-way
ANOVA, Holm–Bonferroni post hoc test). (B and C) Values are mean ± SEM.
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Fig. 5. Compound 1 alleviates pulmonary fibrosis in mice. (A) Mice received
oropharyngeal bleomycin (Bleo) on day 0 to induce pulmonary fibrosis. Control
mice received saline. Mice were then injected with compound 1 (C1) or vehicle
control at the indicated dose daily starting on day 1 and ending on day 20. On
day 21, mice were euthanized and after collecting BAL fluid, lungs were stained
with PicroSirius red to estimate collagen deposition. Images are representative
of three different experiments. (Scale bar: 200 μm.) (B) Quantification of
PicroSirius red staining, n = 3. (C) BAL cell were stained for CD11b, n = 3. Rat
IgG1 was used as the isotype control. (D) After collecting BAL, lungs were
stained for CD11b, n = 3. *P < 0.05, **P < 0.01, ***P < 0.001 (one-way
ANOVA, Holm-Bonferroni post hoc test). (B–D) Values are mean ± SEM.
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Compound 1 Alleviates Pulmonary Fibrosis in Mice. Compound 1
alters macrophage phenotype and inhibits fibrocyte differentia-
tion similar to SAP. Because macrophages and fibrocytes are
implicated in fibrosing diseases (1, 2), we determined whether
DC-SIGN activation by compound 1 in a murine model of pul-
monary fibrosis was sufficient to mimic SAP and alleviate fi-
brosis. As observed before (34), oropharyngeal instillation of
bleomycin resulted in increased collagen deposition and re-
cruitment of CD11b+ macrophages to the lungs (Fig. 5). Daily
injections of compound 1 at doses as low as 0.001 mg/kg de-
creased collagen deposition in the lungs and improved overall
health as indicated by weight change (Fig. 5 A and B and Fig.
S10A). In addition, compound 1 reduced the number of CD11b+
macrophages compared with the bleomycin control (Fig. 5 C and D).
These data suggest that compound 1, similar to SAP, can alle-
viate pulmonary fibrosis and inflammation in mice.
IL-10 Is Necessary for the Antiinflammatory Effect of Compound 1. IL-10
is an antiinflammatory cytokine that is released in response to
DC-SIGN activation (21). IL-10 is also necessary for the antifibrotic
effect of SAP in a mouse model of renal fibrosis (12, 13). As
compound 1 activates DC-SIGN to mimic SAP, we examined the
efficacy of compound 1 on pulmonary fibrosis in IL-10–deficient
mice. In IL-10–deficient mice, bleomycin instillation significantly
increased collagen deposition and CD11b+ and CD11c+ macro-
phages in lungs (Fig. 6). Oropharyngeal instillation of bleomycin
also resulted in significant decrease in body weight (Fig. S10B).
Daily injections of 0.1 mg/kg of compound 1 had no significant
effect on collagen deposition, CD11b+ macrophage accumulation,
CD11c+ cell accumulation, or body weight in IL-10–deficient mice
(Fig. 6 and Fig. S10B). These results suggest that IL-10 is necessary
for the antifibrotic effects of compound 1 in a mouse bleomycin
model of pulmonary fibrosis.
Lung Conducting Airway Epithelial Cells Express SIGNR-R1 and IL-10.
Because compound 1 binds SIGN-R1 to regulate monocyte
functions in mice, we examined the expression of this receptor in
mouse lungs. We found that SIGN-R1 was expressed on Epcam-1+
lung epithelial cells and on CD45+ immune cells (Fig. 7A). To
determine the source of IL-10, we stained mouse lungs for
Epcam-1, CD45, and IL-10 by immunofluorescence. In saline-
treated mice, Epcam-1+ epithelial cells but not CD45+ immune
cells expressed detectable levels of IL-10 (Fig. S11). However,
when mice were treated with bleomycin, the number of IL-10–
expressing epithelial cells (Epcam-1+) significantly decreased
(Fig. 7B and Fig. S11A). This decrease in IL-10+ Epcam-1+ cells
was reversed when mice were injected with compound 1 or SAP
(Fig. 7B and Fig. S11A). These results suggest that compound 1
and SAP can bind to SIGN-R1 on Epcam-1+ epithelial cells to
induce IL-10 expression and reduce inflammation.
Discussion
SAP and CRP bind FcγR and regulate the innate immune system
and fibrosis (8, 12, 18). In this report, we found that in the ab-
sence of all FcγR, SAP still reduces neutrophil adhesion, inhibits
fibrocyte differentiation, and alters macrophage phenotype.
Conversely, CRP requires FcγR to reduce neutrophil adhesion
and promote IL-10 secretion by macrophages, but not to in-
crease ICAM-I+ M1-like macrophages. These observations sug-
gest the presence of additional SAP and CRP receptors. We
identified an additional SAP receptor as DC-SIGN, found that
SAP binds to this receptor in a glycosylation-dependent manner,
and observed that a DC-SIGN ligand mimics some SAP func-
tions in vitro and in animal models of acute lung injury and
pulmonary fibrosis. The DC-SIGN ligand alleviates pulmonary
fibrosis in mice through an IL-10–dependent mechanism, with
the IL-10 most likely originating from the epithelial cells in
the lungs.
The FcγRs have been viewed as the main targets for SAP and
CRP in the innate immune system (5, 18). Our data counter this
view, because SAP is able to regulate the innate immune cells in
absence of all FcγR. In fact, SAP is a more potent polarizer of
FcγR-deficient macrophages than WT macrophages, suggesting
that some of the FcγR may counteract the effect of SAP. In
agreement with this observation, an anti-DC-SIGN antibody
(which contains Fc regions and, thus, interacts with both FcγR and
DC-SIGN) reduced, but did not abolish, neutrophil adhesion,
whereas the F(ab2) fragment of the same antibody was significantly
(P < 0.05 at 1 μg/mL) more potent and a DC-SIGN ligand com-
pletely abolished neutrophil adhesion. A similar trend was ob-
served with SAP, which is a more potent inhibitor of FcγR-
deficient neutrophil adhesion than WT neutrophils. This effect of
FcγR appears to be cell-type dependent, because FcγR and DC-
SIGN seem to act cooperatively to inhibit monocyte to fibrocyte
differentiation. Both DC-SIGN and FcγR regulate the activity of
Src kinases in innate immune cells (35, 36). The antagonism of DC-
SIGN and FcγR signaling in some cells, and the cooperativity of
A B C
Fig. 6. IL-10 is necessary for the antifibrotic effect of compound 1.
(A) Pulmonary fibrosis was induced by bleomycin instillation in IL-
10–deficient mice. The bleomycin-treated mice were then injected with 0.1
mg/kg compound 1 (C1) or an equal volume of vehicle control daily. On day 21,
mice were euthanized and lungs were stained with PicroSirius red to estimate
collagen deposition, n = 3. (B) BAL cells were stained for the indicated markers,
n = 3. Rat IgG1 was used as the isotype control. (C) After collecting BAL, lungs
were stained for the indicated markers, n = 3. *P < 0.05 (one-way ANOVA,
Holm–Bonferroni post hoc test). All values are mean ± SEM.
Fig. 7. Murine lung epithelial cells express SIGN-R1 and IL-10. (A) Mouse lungs
following BAL were stained for the indicated markers. Images are representa-
tive of three different experiments. (Scale bar: 50 μm.) Arrows indicate CD45+
cells expressing SIGN-R1. (B) The number of Epcam-1+ cells expressing IL-10 in
mouse lungs after BAL was quantified, n = 3. *P < 0.05, **P < 0.01, (one-way
ANOVA, Holm–Bonferroni post hoc test). (B) Values are mean ± SEM.
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DC-SIGN and FcγR signaling in other cells, may thus be due to
their differential effects on Src kinases.
Although DC-SIGN/SIGN-R1 is considered to be primarily
expressed by innate immune system cells, the majority of SIGN-R1
staining in mouse lungs was on Epcam-1+ epithelial cells. These
SIGN-R1+ Epcam-1+ expressed high levels of IL-10. Following a
bleomycin insult, at day 21, although there was no appreciable
reduction in the number of Epcam-1+ cells, there was a significant
decrease in the number of IL-10+ Epcam-1+ cells. IL-10 inhibits
apoptosis of epithelial cells (37) and increases the clearance of cell
debris (38). As such, up-regulation of IL-10 by SAP or compound 1
may have a protective effect on lungs by limiting tissue damage
and inflammatory responses. A similar role has been observed
for epithelial cell-derived IL-10 in mouse models of in-
flammatory bowel disease (39). Alternatively, it is possible that
IL-10 expression in SIGN-R1+ epithelial cells is a function of
their health. However, this possibility is unlikely because our
studies in IL-10–deficient mice suggest a critical role for IL-10 in
the antifibrotic role of compound 1.
Together, our data indicate that SAP binds DC-SIGN/SIGN-
R1 to regulate innate immune cells and epithelial cells. Through
its interaction with DC-SIGN, SAP distinguishes itself func-
tionally from CRP. This observation suggests that DC-SIGN/
SIGN-R1 is a key regulator of the innate immune system and is
thus an interesting therapeutic target. Additionally, the func-
tional interaction of SAP and PTX3 with DC-SIGN suggest that
these pentraxins may regulate dendritic cells and, thus, the
adaptive immune system.
Materials and Methods
All animals were used in accordance with National Institutes of Health
guidelines and with a protocol approved by the Texas A&M University In-
stitutional Animal Care and Use Committee. Human blood was obtained
with written consent and with specific approval from the Texas A&M Uni-
versity human subjects Institutional Review Board. Human recombinant SAP
and CRP were expressed in HEK293 cells and then purified y using affinity
purification (8). Human PBMC, human neutrophils, mouse spleen cells, and
mouse neutrophils were isolated and then incubated with antibodies and
pentraxins, as described before (8, 9). Human monocytes were differentiated
into macrophages in serum containing medium and then polarized for 3 d in
serum-free medium. Pulmonary fibrosis and acute lung injury in mice were
induced by bleomycin instillation (9, 40). Detailed information about mice,
experimental procedures, and statistical analyses can be found in SI Mate-
rials and Methods.
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